undamentalytics Newsletter
Sign in

Incannex Healthcare Inc. (IXHL) stock

Add to watchlist

Add holding +

NASDAQ: IXHL Nasdaq Biotechnology

Incannex Healthcare Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.

Incannex Healthcare Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds10 adding, 13 cuttingOf 3 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 70% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 104% and a beta of 1.4 against the S&P 500.

Latest results

Earnings per share
-$0.17 against an average estimate of -$0.57: beat by 70.2%

Incannex Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.7%
  • 1 week-4.0%
  • 1 month-21.7%
  • This year-77.8%
  • 1 year-76.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Incannex Healthcare Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Incannex Healthcare Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.22 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Incannex Healthcare Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.23 +1% — 0%
Next −$2.44 −10% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −7.4% on 90 days ago. In the last 30 days, 1 analyst raised Incannex Healthcare Inc.'s forecast and 0 cut it.

Consensus EPS forecast Incannex Healthcare Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.41 Current fiscal year, 60 days ago: −$2.41 Current fiscal year, 30 days ago: −$2.41 Current fiscal year, 7 days ago: −$2.41 Current fiscal year, Now: −$2.23 −$2.23 Next fiscal year, 90 days ago: −$2.62 Next fiscal year, 60 days ago: −$2.62 Next fiscal year, 30 days ago: −$2.62 Next fiscal year, 7 days ago: −$2.62 Next fiscal year, Now: −$2.44 −$2.44

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.41−$2.62
60 days ago −$2.41−$2.62
30 days ago −$2.41−$2.62
7 days ago −$2.41−$2.62
Now −$2.23−$2.44

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.57 −$0.17 +70.2%
Mar 2026 −$0.84 −$0.49 +41.7%
Dec 2025 −$0.93 −$0.85 +8.7%
Sept 2025 −$18.09 −$0.92 +94.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Incannex Healthcare Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.3%
of tradable shares
Days to cover
4.45
at average volume
Short interest, 1 month
−43%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
9.1%
of shares
Employees
12
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
IXHL−59%−54%−83%−78%
Industry peers (median)−17%−28%−5%−26%
S&P 500+26%+25%+18%+11%
Months that ended higher
IXHL17%42%33%27%
S&P 50067%75%75%46%
Largest fall from a high during the year
IXHL−77%−76%−96%−81%
S&P 500−10%−8%−19%−9%

Worst fall since March 2, 2022: 100% from March 15, 2022 to November 2, 2026. Getting back needed a 178892% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.38 – $14.37
From 52-week high
−83.4%
vs 50-day average
−24.7%
vs 200-day average
−42.7%
Volatility (1 year)
104%
Beta vs S&P 500
1.45

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$1.7M
Institutions reporting
15
Shares held vs prior quarter
▼ 64.8%
Positions opened / closed
6 / 11

Top buyers and sellers, Q2 2026: 10 institutions bought and 13 sold ; the biggest buyer was Millennium Management LLC (+95K shares) and the biggest seller Polar Asset Management Partners Inc (−625K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
LPL Financial LLC $557,149 148K 32.6% ▲ 108.2%
Millennium Management LLC $358,148 95K 20.9% New
Jane Street Group, LLC $294,013 78K 17.2% New
Advisorshares Investments LLC $228,864 61K 13.4% ▲ 148.4%
Susquehanna International Group, LLP $108,179 29K 6.3% New
Commonwealth Equity Services, LLC $52,750 14K 3.1% ▲ 15.8%
Citadel Advisors LLC $38,912 10K 2.3% New
Osaic Holdings, Inc. $23,970 6K 1.4% 0.0%
UBS Group AG $13,574 4K 0.8% ▼ 91.1%
Morgan Stanley $13,378 4K 0.8% ▲ 72.3%
Citigroup Inc $10,581 3K 0.6% New
Quent Capital, LLC $7,249 2K 0.4% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Incannex Healthcare Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Incannex Healthcare Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Incannex Healthcare Inc. in brief

What does Incannex Healthcare Inc. do?
Incannex Healthcare Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.
What is Incannex Healthcare Inc.'s stock ticker?
Incannex Healthcare Inc. trades under the ticker IXHL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Incannex Healthcare Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are LPL Financial LLC, Millennium Management LLC and Jane Street Group, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.